Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK similarity study of AVT32-DRL_PB versus Keytruda in resected melanoma
PACTR202607535799083Not yet recruiting
- Sponsor
- Alvotech
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of pembrolizumab in cutaneous melanoma (CM) (2 arms), sponsored by Alvotech. Primary endpoints: Area under the concentration-time curve from time 0 to 3 weeks and Area under the concentration-time curve over the dosing interval at steady state. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on PACTR202607535799083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607535799083.